Barr Drops Suit Vs. FDA Over Allegra Marketing Exclusivity
In February, Barr sued the FDA in the U.S. District Court for the District of Columbia to challenge its decision to make the company share its 180-day marketing exclusivity.
Under its existing policies, the FDA awards marketing exclusivity based on each patent filed in the Orange book, which can result in multiple companies having to share...
Already a subscriber? Click here to login